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Abstract
Head and Neck cancer (HNC) comprises a heterogeneous group of upper aerodigestive tract 
malignant neoplasms the most frequent of which is squamous cell carcinoma. HNC forms the 
eighth most common cancer type and the incidence is increasing. However, survival has improved 
only moderately during the past decades. Currently, early diagnosis remains the mainstay for 
improving treatment outcomes in this patient population. Unfortunately, screening methods to 
allow early detection of HNC are not yet established. Therefore, many cases are still diagnosed at 
advanced stage, compromising outcomes. Exhaled breath analysis (EBA) is a diagnostic tool that 
has been recently introduced for many cancers. Breath analysis is non-invasive, cost-effective, 
time saving, and can potentially be applied for cancer screening. Here, we provide a summary of 
the accumulated evidence on the feasibility of EBA in exhaled breath analysis the diagnosis of 
HNC.
Keywords: Head and neck cancer; Exhaled breath analysis; Diagnosis.
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Introduction  
Head and Neck Cancers (HNCs) constitute a heterogenous group of neoplasms. A recent report 
based on GLOBOCAN database estimated the diagnosis of more than 500 000 new cases of HNC 
during 2018 1, and incidence is expected to continue increasing according to estimates for 2030 2. 
HNC is associated with high mortality 1, and one of the main reasons for the low survival can be 
explained by late stage of diagnosis. As a result, the development of effective early detection 
strategies is seen as an important approach to improve curative treatment outcomes 3,4.
Current methods to detect HNCs include visual inspection of the upper aerodigestive 
mucous membranes and pathological examination of tissue biopsy of suspicious lesions. 
Serological and salivary biomarkers are under evaluation to aid in the early primary diagnosis or 
follow-up surveillance of this patient population, but none has yet been proven useful in clinical 
practice 5,6. Therefore, more reliable and non-invasive methods are warranted for early diagnosis 
of HNC. The purpose of this review is to provide a summary of the existing evidence on the 
feasibility of exhaled breath analysis (EBA) in the diagnosis of HNC.
Exhaled breath analysis
Non-invasive approaches to the early diagnosis of cancer are crucial topic of research. Available 
methods include, for example, surface brushing, saliva and blood sampling. The aim of these 
approaches is to identify cancer biomarkers or signatures that would allow early detection of cancer 
before any clinical symptoms or signs develop. Such early diagnosis could lead to identification, 
treatment planning and intervention of the disease at an early stage and that, indeed, could improve 
clinical outcome 7. However, routine diagnosis of many cancers (including those of head and neck) 
is still based on evaluation of changes in macroscopic appearance, radiological features and 
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histopathological characteristics. The tools that are used in this traditional evaluation are not easily 
applicable in population screening as these diagnostic examinations are invasive, expensive, and/or 
time-consuming, and may involve exposure to radiation. 
In contrast, analysis of exhaled breath may represent a non-invasive, rapid and inexpensive 
screening tool that has shown promising results in many cancers 8-14. Easy access to sample supply 
is one of main advantages of breath analysis. The main gas phase constituents of exhaled breath 
are carbon dioxide, nitrogen, oxygen, water vapor and argon. In addition to these compounds, 
many volatile organic compounds (VOCs) are present at trace amounts, from part-per-million 
(ppm, 10-6) to down to part-per-trillion (ppt, 10-12) levels. VOCs can be transferred to blood either 
in the lungs via gas exchange between alveoli and blood or they can be released in the lower or 
upper airways (including the oral and nasal cavity) 15. These volatile species can be analyzed in 
the gas phase using various mass spectrometry techniques, optical spectroscopy 16 or sensors based 
on, for example, nanoparticles or semiconductive metal oxides 17. In addition to sampling the 
exhaled gas, breath samples can also be collected by condensing the breath on a cooled surface. 
The so-called exhaled breath condensate (EBC) is composed mostly of condensed water vapor but 
will also include small amounts of respiratory droplets containing nonvolatile molecules and 
water-soluble volatile compounds 18 as well as bacteria and viruses 19. The content of the EBC can 
be analyzed, for example, using enzyme immunoassay kits or chromatography – mass 
spectrometry techniques. The theory of exhaled breath analysisEBA for cancer diagnosis is based 
on the concept that cancer initiation is associated with increase in oxidative stress that can cause 
alteration in the profile of deoxyribonucleic acid (DNA), proteins and other components 20. Such 
alterations can be detected in exhaled breath as increased or decreased concentrations of 
biomarkers connected with a specific disease that is associated with specific pathologic changes 
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21,22. The history of research on breath analysis is strongly associated with Linus Pauling, the Nobel 
Prize winner in 1971, who explained that human breath is a complex gas mixture containing more 
than 200 VOCs 23. To date, almost 900 different VOCs have been detected in exhaled breath 24. 
Methodological aspects in exhaled breath analysis
Collection procedure: The collection procedure for a breath sample depends on whether the aim 
is to collect the gas phase portion of breath or the EBC. For gas phase samples, breath is either 
collected to sorbent materials or sample bags (offline analysis) or it can be analyzed immediately 
after the sample collection (online analysis). Storage in sorbent tubes or bags introduces risks 
related to sample stability during handling and storage 25. Exhalations can be divided into three 
phases. The brief initial phase contains gas from the oral cavity and trachea, this is often called 
“dead space phase”. The next phase is the mixed expiratory phase in which gas from the lungs and 
lower airways mixes with the dead space sample. The final phase is the end-tidal, which most 
closely reflects alveolar gas in the lungs. In most applications of breath analysis, the focus is on 
collecting the end-tidal phase and the first two phases are discarded. This can be done by real-time 
monitoring of the carbon dioxide content during sampling. Carbon dioxide originates fully from 
the alveolar gas-exchange and can be used as a marker for the end-tidal phase 25. However, in the 
case of HNC, the first two phases should not be discarded as they should contain the most relevant 
biomarkers for cancers in the upper aerodigestive tract. 
Exhaled breath is saturated with water at the temperature of the airways. If the temperature 
of the breath sample is lowered, condensation occurs. The EBC is normally collected at 
temperatures below 4 °C. Collecting devices for EBC use several different types of cooling 
maneuvers such as dry ice, wet ice with salt, and liquid nitrogen, and accordingly the condensate 
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can be either liquid, solid or mix of both 26,27. EBC analysis is always performed offline. 
Importantly, it has been reported that the condensation temperature could affect different 
biomarkers’ concentration and therefore, reporting the condensation temperature is essential for 
process standardization and registration 27. There is a wide variety of commercial  EBC collection 
devices such as EcoScreen Turbo 28, TURBO-DECCS 29, RTubeTM 30, and devices for specific 
patient groups e.g. infants and children 31-33, and mechanically ventilated patients 34. 
Duration of sample collection: Duration of sample collection is dependent on the used technique. 
For gas phase sampling, the sampling time can be as short as the duration of a single exhalation 
(seconds). When collecting the breath on a sorbent material, the concentrations of the analyte gases 
can be enriched by using longer sampling times (minutes). In bag or online sampling, several 
samples can be acquired in succession to reduce the inter-individual variation of breath levels. 
Various physiological factors, such as breath holding, increased tidal volume and hyperventilation 
can have an influence on the retrieved breath concentrations but no universal breath gas sampling 
procedure currently exists. Some specific breath tests, which are already in clinical use have been 
standardized, an example being the fractional nitric oxide (FeNO) test for measuring airway 
inflammation 35. 
Although the majority of published studies recommend EBC sample collection of 10 to 30 
minutes, some studies have reported short collection times of 3 minutes and others prolong the 
time up to 60 minutes 36. The approximate volume of exhaled breath condensateEBC after 10 to 
15 minutes of breathing is 1-3 ml 37. Clearly, the length of sample collection time has a direct 
effect on the final volume 36. Increased tidal volume and/or minute ventilation, hyperventilation 
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and mechanical ventilation are all associated with an increase in the volume of exhaled breath 
condensateEBC 38-40.
Sample storage: When using offline gas phase samples, the storage temperature and time depend 
on whether the sample is stored in a bag or a sorbent material. The optimal temperature for bag 
storage is 37 °C to avoid water condensation on bag surfaces. Storage losses depend heavily on 
the specific biomarkers and the collection bag material. Bags manufactured from Tedlar have been 
shown to be stable for many compounds for up to 6 hours of storage 41. For samples collected onto 
a sorbent tube, a stable storage time of 1.5 months was achieved at – 80 °C. However, of almost 
600 compounds that were studied, a significant amount showed discernible levels of change in 
concentration after six months of storage 42. 
The optimum temperature for an EBC sample storage is below -70oC. However, some 
biomarkers require assessment of their stability at the storage temperature. Furthermore, division 
of the exhaled breath samples into aliquots is recommended as repetitive freezing and thawing for 
analysis may result in breakdown of certain compounds such as nucleic acids and prostaglandins 
43. These parameters do vary between the investigated individual markers.
Potential contamination by saliva and oral bacterial activity: Salivary contamination can occur 
during collection of EBC and it is an important confounding factor, especially when analyzing 
volatile biomarkers. A clear example of salivary contamination is that exhaled breath nitrite levels 
are mostly attributable to oropharyngeal bacterial flora, as their levels decrease drastically 
following rinsing of the mouth with a chlorhexidine solution 44. Salivary contamination can be 
prevented or minimized by using a saliva trap and by placing the exhaled breath condenser at a 
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higher level than mouth and thus making it unlikely for saliva to enter the collecting device 18. 
Exclusion of saliva contamination can be done by testing salivary amylase in the EBC sample 45,46. 
Additionally, the ATS/ERS Task Force on EBC recommend using a nasal clip to minimize the 
entry of nasal airway lining fluid into the sampled air and to ensure that all exhaled air will pass 
through the mouth 18. Oral bacteria and oral enzymatic activity can also influence the exhaled gas 
concentrations. For example, exhaled ammonia is mainly produced by enzymatic hydrolysis of 
urea in the oral cavity 47. The contribution of the oral cavity to the exhaled gas concentrations can 
be minimized by the use of an antiseptic 48.
Potential breath biomarkers of HNC
In many neoplasms, exhaled breath has been a rich source of potential cancers biomarkers 20,49,50. 
These biomarkers can be divided into three categories. The first category includes the small 
volatile compounds. These can be measured in the gas phase and, in the case of water-soluble 
compounds also in the breath condensate (e.g. ammonia and formic acid). The second category 
includes biomolecules of low-molecular weight (e.g. isoprostanes, polypeptides and nucleic acids). 
The third category is miscellaneous including many compounds such as lipid mediators, 
chemokines and cytokines. The second and third category are mainly present in the breath 
condensate. DNA from exhaled breath condensateEBC of healthy people has been used to identify 
mutations (e.g. TP53 gene mutations) that are associated with early neoplastic changes 51. A recent 
study recognized several volatile organic compounds as breath gas biomarkers of thyroid cancer 
49. Reported potential breath gas biomarkers for oral squamous cell carcinoma are alkanes, alkenes 
and aldehydes including undecane, dodecane, decanal, benzaldehyde, 3,7-dimethyl undecane, 4,5-
dimethyl nonane, 1-octene, and hexadecane when analyzed by solid-phase microextraction with 
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gas chromatography-mass spectrometry 52. By using linear discriminant analysis classification of 
these compounds, well-defined clusters for patients and controls have been revealed 52. In addition, 
dimethyl disulfide, decamethylcyclopentasiloxane (D5) and p-xylene (PX) have been reported as 
gas phase biomarkers that decrease after surgery 53. Ethanol, 2-propenenitrile and undecane have 
also been identified as exhaled gas biomarkers that could distinguish laryngeal and pharyngeal 
head and neck squamous cell carcinoma from benign tumors and from healthy subjects 54.
Exhaled breath analysis as a diagnostic tool in head and neck cancer
Recent research has analyzed exhaled breath to aid in early detection of HNC 22,52,55. An early 
attempt to analyze exhaled breath for diagnosis of HNC was conducted by Hakim et al. (2011) 22 
who used breath gas testing with an artificial nose based on gold nanoparticle sensors. They were 
able to recognize patients with HNC from healthy people and from patients with lung cancer 22. 
The nanoparticle sensors did not provide identification of the biomarkers responsible for the sensor 
response. A few years later, Gruber et al. 54 in their analysis of exhaled breath from patients with 
laryngeal and pharyngeal cancers found that ethanol, 2-propenenitrile and undecane can be used 
as potential biomarkers for these two cancers. Using artificially intelligent nanoarrays, Nakhleh et 
al. 56 identified a set of many diseases including HNC from exhaled breath. In oral squamous cell 
carcinoma, a recent study used exhaled breath analysisEBA and found three compounds 
(benzaldehyde, 3,7-dimethylundecane, and butyl acetate) that have a relationship with pathological 
parameters of these cancers 52. The methods used for EBA of HNC patients so far include gas 
chromatography-mass spectrometry 51, various nanomaterial-based sensors 22,53,55 and chemical 
ionization mass spectrometry 54.
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Exhaled breath analysis as a predictive tool to monitor the treatment outcome
Assessment of treatment outcome is of great importance during follow-up for early identification 
of patients with residual or recurrent disease. Exhaled breath analysisEBA has been recently 
introduced as an effective tool for monitoring response to treatment in lung cancer 57. In HNC, 
Hakim et al 22 suggested that breath analysis using an artificial nose could be utilized as a test to 
follow-up after treatment of HNC especially for those cases at high-risk of developing second 
primary tumors. Moreover, breath analysis from cured patients who underwent resection of HNC 
was similar to breath analysis of healthy control, which potentially indicates a successful surgery 
58. Interestingly, Hartwig et al. 53 collected breath samples before and after surgical treatment of 
oral squamous cell carcinoma and compared the breath analysis for each case. They reported 
disappearance of cancer-associated volatile organic compounds in the breath after treatment 53. 
However, using breath analysis in monitoring the treatment of HNC is still a new field of research 
that requires more scientific efforts. Also, the protocols would need to define further steps in the 
management of the patient population with positive findings in their breath samples.
Conclusion and Future
In recent years, exhaled breath analysisEBA has received increasing research interest in the early 
detection of many cancers. The currently available body of evidence refers to potential clinical use 
of exhaled breath in the early diagnosis of HNC. Such evidence requires further validation in large 
cohorts with comparison of different protocols that have been developed. That will allow 
standardization of the methods of breath sampling, including sample collection, storage, and 
analysis. It is noteworthy, that a recent review proposed a framework for conducting and reporting 
future studies investigating the role of VOCs in cancer diagnosis 59. Translation of breath analysis 
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from lab into clinic, after generalizability of the currently identified biomarkers, could be a step 
toward early detection of HNC through screening of high-risk populations. 
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